Windward Bio Group AG
corporate_fare Company Profile
Windward Bio Group AG (NASDAQ:WWB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for WWB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for WWB spans 4, 6-K.
Recent high-impact activity:
- OrbiMed Buys $20M of Windward Bio IPO Shares at $17.00
- Director Stampacchia Buys $29.75M of Windward Bio IPO Shares at $17.00
- Windward Bio Closes $251.2M IPO and Sanofi Placement at $17.00
- Windward Bio Closes IPO and Placement With $251.2M, Sanofi In for $50M
- Windward Bio Raises $175M in IPO Priced at $17 a Share
Short Interest & Short Volume
On November 19, 2026, 57.5% of WWB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for WWB, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.
IPO and Sanofi Placement Close · Dilution From New Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
WWB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.